v3.26.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Operating expenses:    
Research and development $ 9,340,959 $ 7,251,097
General and administrative 10,492,554 8,114,654
Total operating expenses 19,833,513 15,365,751
Loss from operations (19,833,513) (15,365,751)
Other income, net 138,018 343,724
Change in fair value of convertible promissory notes (1,153,421)
Net loss $ (20,848,916) $ (15,022,027)
Net loss available to common stockholders per share of common stock, basic [1] $ (21.58) $ (44.96)
Net loss available to common stockholders per share of common stock, diluted [1] $ (21.58) $ (44.96)
Weighted average number of shares used in calculating net loss per share, basic [1] 966,124 334,133
Weighted average number of shares used in calculating net loss per share, diluted [1] 966,124 334,133
[1] Retroactively restated for one-for-twenty-eight share reverse stock split effected on June 27, 2025.